This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.

Inclusion Criteria:

• Have been diagnosed with prostate cancer.
• Have a rising PSA while on hormone therapy or following surgical castration.

Exclusion Criteria:

• Have evidence of distant metastatic disease on screening bone scan or CT scan.
• Have received cytotoxic chemotherapy.
• Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.